Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Ren Nutr ; 30(1): 46-52, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-30956090

RESUMEN

OBJECTIVE(S): Low protein diets (LPD; 0.6 g/kg/day), prescribed for nondialysis chronic kidney disease (CKD) patients, have demonstrated numerous benefits. LPDs may modulate inflammation and oxidative stress through the nuclear factor erythroid 2-related factor 2 (Nrf2), which encodes antioxidant and phase II detoxifying enzymes. LPDs also inhibit or antagonize nuclear factor kB (NF-kB) activity, which orchestrates inflammatory and oxidative stress responses. The objective of this study was to evaluate the effects of LPD on Nfr2 and NF-κB messenger RNA (mRNA) expression in nondialysis CKD patients. METHODS: In this longitudinal study, a LPD was prescribed for 30 nondialysis CKD patients for 6 months. Peripheral blood mononuclear cells were isolated, and quantitative real-time polymerase chain reaction analysis was performed to evaluate Nrf2, NF-κB, and NADPH quinine oxidoreductase-1 mRNA expression. Thiobarbituric acid-reactive substance (TBARS) levels, a marker of lipid peroxidation, were also evaluated. RESULTS: (Age 55.5 ± 14.0 years; body mass index 29.1 ± 5.9 kg/m2; glomerular filtration rate 35.6 ± 12.2 mL/minute). After 6 months of nutritional intervention, Nrf2 mRNA expression increased from 0.85 (0.47-1.56) to 1.28 (0.63-2.63) nmol/mL (P = .03), and TBARS levels were significantly decreased from 1.78 (1.31-2.38) to 1.30 (1.07-2.22) nmol/mL (P = .04). NF-κB mRNA expression showed no significant difference after 6 months, but the Nrf2/NF-κB ratio was increased. CONCLUSION(S): In this study, a LPD appeared to modulate Nrf2 expression and decrease the levels of TBARS in nondialysis CKD patients. However, more studies are needed to confirm the effectiveness of LPD on the modulation of transcription factors involved with oxidative stress and inflammation in nondialysis CKD patients.


Asunto(s)
Dieta con Restricción de Proteínas/métodos , Expresión Génica/genética , Factor 2 Relacionado con NF-E2/sangre , Factor 2 Relacionado con NF-E2/genética , Insuficiencia Renal Crónica/sangre , Insuficiencia Renal Crónica/genética , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad
2.
Biochemistry ; 58(15): 2054-2060, 2019 04 16.
Artículo en Inglés | MEDLINE | ID: mdl-30912928

RESUMEN

Recent studies have suggested that uremic toxins such as indoxyl sulfate (IS) and indole-3-acetic acid (IAA) from the metabolism of the gut microbiota may be involved in the inflammatory signaling pathway in chronic kidney disease (CKD) patients through the activation of the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor. The objective of this study was to investigate the possible relationship between uremic toxins (IS and IAA) and AhR protein expression in CKD patients. A cross-sectional observational study involving 17 hemodialysis (HD) [11 men, 55.5 ± 11.7 years of age, 54.0 (25.5-136.0) months of HD, body mass index (BMI) of 25.8 ± 3.8 kg/m2] and 15 non-dialysis-dependent (NDD) CKD (8 men, 54.1 ± 18.2 years of age, glomerular filtration rate of 34.8 ± 21.0 mL/min/1.73 m2, BMI of 27.4 ± 5.0 kg/m2) patients was conducted. IS and IAA levels were measured by reversed-phase high-performance liquid chromatography, and the protein expression levels of AhR and nuclear factor κ B (NF-κB) were evaluated by a Western blot assay. There was no difference in the expression of either AhR or NF-κB in the patients, and as expected, uremic toxin levels were higher in HD patients than in NDD patients. In the overall analysis, AhR protein expression was positively associated with IAA plasma levels ( r = 0.4; p = 0.03) and NF-κB protein expression ( r = 0.62; p = 0.001). Although the role of AhR in inflammation and CVD in CKD patients is far from being completely understood, the association between IAA and AhR observed in this study suggests a possible role for uremic toxins in the cell signaling pathway involved in inflammation in CKD patients.


Asunto(s)
Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Microbioma Gastrointestinal/fisiología , Receptores de Hidrocarburo de Aril/metabolismo , Insuficiencia Renal Crónica/fisiopatología , Toxinas Biológicas/metabolismo , Adulto , Anciano , Bacterias/metabolismo , Estudios Transversales , Femenino , Tracto Gastrointestinal/metabolismo , Tracto Gastrointestinal/microbiología , Humanos , Indicán/metabolismo , Ácidos Indolacéticos/metabolismo , Masculino , Persona de Mediana Edad , FN-kappa B/metabolismo , Insuficiencia Renal Crónica/terapia , Transducción de Señal
3.
J Bras Nefrol ; 40(3): 225-232, 2018.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-29944154

RESUMEN

INTRODUCTION: Chronic Kidney disease (CKD) patients have a high prevalence of cardiovascular mortality, and among the risk factors are dyslipidemia and obesity, common findings in the early stages of CKD. The aim of this study was to evaluate the effects of low protein diet (LPD) on the lipid and anthropometric profile in non-dialysis CKD patients. METHODS: Forty CKD patients were studied (20 men, 62.7 ± 15.2 years, glomerular filtration rate (GFR) 26.16 ± 9.4 mL/min/1.73m2). LPD (0.6g/kg/d) was prescribed for six months and, biochemical and anthropometric parameters like body mass index (BMI), waist circumference and body fat mass (assessed by dual X-ray absorptiometry - DXA) were evaluated before and after six months with LPD. RESULTS: After six months of nutritional intervention, patients presented reduction on BMI (from 28.1 ± 5.6 to 27.0 ± 5.3 Kg/m2, p = 0.001), total cholesterol (from 199.7 ± 57.1 to 176.0 ± 43.6mg/dL, p = 0.0001), LDL (from 116.2 ± 48.1 to 97.4 ± 39.1 mg/dL, p = 0,001) and uric acid (from 6.8 ± 1.4 to 6.2 ± 1.3 mg/dL, p = 0.004). In addition, GFR values were increased from 26.2 ± 9.5 to 28.9 ± 12.7mL/min (p = 0.02). The energy, proteins, cholesterol and fiber intake were reduced significantly. CONCLUSION: LPD prescribe to non-dialysis CKD patients for six months was able to improve some cardiovascular risk factors as overweight and plasma lipid profile, suggesting that LPD can be also an important tool for protection against cardiovascular diseases in these patients.


Asunto(s)
Tamaño Corporal , Colesterol/sangre , Tratamiento Conservador , Dieta con Restricción de Proteínas , Insuficiencia Renal Crónica/sangre , Insuficiencia Renal Crónica/terapia , Triglicéridos/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad
4.
J. bras. nefrol ; 40(3): 225-232, July-Sept. 2018. tab
Artículo en Inglés | LILACS | ID: biblio-975916

RESUMEN

ABSTRACT Introduction: Chronic Kidney disease (CKD) patients have a high prevalence of cardiovascular mortality, and among the risk factors are dyslipidemia and obesity, common findings in the early stages of CKD. The aim of this study was to evaluate the effects of low protein diet (LPD) on the lipid and anthropometric profile in non-dialysis CKD patients. Methods: Forty CKD patients were studied (20 men, 62.7 ± 15.2 years, glomerular filtration rate (GFR) 26.16 ± 9.4 mL/min/1.73m2). LPD (0.6g/kg/d) was prescribed for six months and, biochemical and anthropometric parameters like body mass index (BMI), waist circumference and body fat mass (assessed by dual X-ray absorptiometry - DXA) were evaluated before and after six months with LPD. Results: After six months of nutritional intervention, patients presented reduction on BMI (from 28.1 ± 5.6 to 27.0 ± 5.3 Kg/m2, p = 0.001), total cholesterol (from 199.7 ± 57.1 to 176.0 ± 43.6mg/dL, p = 0.0001), LDL (from 116.2 ± 48.1 to 97.4 ± 39.1 mg/dL, p = 0,001) and uric acid (from 6.8 ± 1.4 to 6.2 ± 1.3 mg/dL, p = 0.004). In addition, GFR values were increased from 26.2 ± 9.5 to 28.9 ± 12.7mL/min (p = 0.02). The energy, proteins, cholesterol and fiber intake were reduced significantly. Conclusion: LPD prescribe to non-dialysis CKD patients for six months was able to improve some cardiovascular risk factors as overweight and plasma lipid profile, suggesting that LPD can be also an important tool for protection against cardiovascular diseases in these patients.


RESUMO Introdução: Pacientes com Doença Renal Crônica (DRC) possuem alta prevalência de mortalidade cardiovascular e, dentre os fatores de risco, encontram-se alterações no perfil lipídico e excesso de peso, que são achados comuns na DRC. O objetivo deste estudo foi avaliar os efeitos da dieta hipoproteica sobre o perfil antropométrico e lipídico de pacientes com DRC em tratamento conservador. Métodos: Foram estudados 40 pacientes com DRC (20 homens, 62,7 ± 15,2 anos, e Taxa de Filtração Glomerular (TFG) de 26,2 ± 9,4 mL/min/1,73m2). Os pacientes receberam prescrição de dieta hipoproteica (0,6g/kg/d) e parâmetros bioquímicos e antropométricos como índice de massa corporal (IMC), circunferência da cintura (CC) e percentual de gordura corporal (GC) avaliado por absorciometria com raio-x de dupla energia (DXA), foram analisados antes e após 6 meses de intervenção. Resultados: Os pacientes apresentaram após 6 meses, redução do IMC (de 28,1 ± 5,6 para 27,0 ± 5,3Kg/m2, p = 0,001), colesterol total (de 199,7 ± 57,1 para 176,0 ± 43,6mg/dL, p = 0,0001), LDL (de 116,2 ± 48,1 para 97,4 ± 39,1 mg/dL, p = 0,001) e ácido úrico (de 6,8 ± 1,4 para 6,2 ± 1,3 mg/dL, p = 0,004) e, aumento da TFG de 26,2 ± 9,5 para 28,9 ± 12,7mL/min (p = 0,02). Houve redução significativa na ingestão de energia e proteínas, bem como de colesterol e fibras. Conclusão: A intervenção com dieta hipoproteica para pacientes com DRC em tratamento conservador por seis meses foi capaz de melhorar alguns fatores de risco cardiovascular, como o excesso de peso e o perfil lipídico plasmático, sugerindo que a dieta hipoproteica, além de outros benefícios pode também ser importante ferramenta para a proteção de doenças cardiovasculares nesses pacientes.


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Colesterol/sangre , Dieta con Restricción de Proteínas , Tamaño Corporal , Insuficiencia Renal Crónica/sangre , Insuficiencia Renal Crónica/terapia , Tratamiento Conservador , Triglicéridos/sangre
5.
Nutr. hosp ; 30(4): 831-836, oct. 2014. ilus, tab
Artículo en Inglés | IBECS (España) | ID: ibc-134913

RESUMEN

Diabetes is a complication which occurring during gestation might substantially influence the development of offspring during fetal life and postnatally. Flaxseed is a source of omega-3, that the appropriate supply during gestation and lactation are determinant for a suitable perinatal growth and development. The present study aimed to assess beneficial effects of the use of flaxseed flour during pregnancy and lactation on body development from birth to weaning of offspring from diabetic mothers. Methods: twelve rats from a total of eighteen were induced to diabetes by high-fat diet during four weeks, also receiving one lower dose of streptozotocin. After confirmation of diabetes (glucose>300mg/dL), they were mated and when pregnancy was confirmed, they were divided in3 groups: high-fat group (HFG), high-fat flaxseed flour group (HFFFG) and control group (CG), receiving high-fat diet, high-fat diet added flaxseed flour and control diet, respectively. They were fed this way during whole gestation and lactation. The body development of offspring was measured weekly since the first day after birth until weaning. Results: At birth, the average body mass of offspring from diabetics mothers who received only high-fat diet was 23,6% lighter than body mass of offspring from non-diabetics mothers (p<0,05), while the animals from diabetic mothers who consumed flaxseed flour during pregnancy and lactation showed the same body mass than the control group. During all experiment HFFFG group showed decreased body mass (about 20%, p<0,05) in comparison with control group. Conclusion: The treatment with flaxseed flour was capable of avoiding lower birth weight in offspring from diabetic mothers. However, the consumption of flour by mothers during lactation yielded decrease offspring weight at weaning (AU)


La diabetes es una complicación que ocurre durante la gestación puede influir sustancialmente el desarrollo delas crías durante la vida fetal y postnatal. La linaza es una fuente de ácidos grasos omega-3, que la oferta apropiado durante la gestación y lactancia son determinantes para un adecuados crecimiento y desarrollo perinatal. Este estudio tuvo como objetivo evaluar los efectos beneficiosos del uso de la harina de linaza durante el embarazo y la lactancia en el desarrollo corporal desde el nacimiento hasta el destete de las crías de madres diabéticas. Métodos: Los doce ratas, de un total de dieciocho fueron inducidas a la diabetes con dieta alta en grasas durante cuatro semanas también recibir una dosis reducida de estreptozotocina. Después de la confirmación de la diabetes (glucosa> 300mg/dL), que fueron apareadas y cuando se confirmó el embarazo, fueron divididos en 3 grupos: grupo de alto contenido de grasa (HFG), grupo de alto contenido de grasa con harina de linaza (HFFFG)y grupo control (GC ), recibiendo la dieta alta en grasas, dieta alta en grasa añadida harina de linaza y dieta control, respectivamente. Fueron alimentados de esta manera durante toda la gestación y la lactancia. El desarrollo corporal de las crías se midió semanalmente desde el primer día después de su nacimiento hasta el destete. Resultados: En el nacimiento, la masa corporal medio de las crías de madres diabéticas que recibieron sólo la dieta rica en grasas era 23,6% más ligero que la masa corporal de las crías de los no diabéticos madres (p<0,05), mientras que los animales de la diabetes madres que consumieron la harina linaza durante el embarazo y la lactancia mostraron la misma masa corporal que el grupo control. Durante todo el grupo HFFFG experimento mostró masa corporal disminuido (20%, p <0,05) en comparación con el grupo control. Conclusión: El tratamiento con harina linaza fue capaz de evitar bajo peso al nacer en los hijos de madres diabéticas. Sin embargo, el consumo de harina de linaza por las madres durante la lactancia cedió disminuir el peso crías al destete (AU)


Asunto(s)
Humanos , Lino , Semillas , Extractos Vegetales/farmacocinética , Nutrición Materna , Diabetes Mellitus/dietoterapia , Lactancia Materna , Recién Nacido de Bajo Peso/crecimiento & desarrollo , Embarazo en Diabéticas
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda